FdaApplication
NDA 220641
Identifiers
- fda_app_no: NDA220641
Properties
| Property | Value |
|---|---|
| applicant_name | CORCEPT THERAPEUTICS INC |
| application_type | NDA |
| approval_date | 2026-03-25 |
Revenue by product
LIFYORLI (COPACKAGED)
| Period | Revenue |
|---|---|
| Q2 2026 | $47.6M |
| Q2 2025 | $0.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| LIFYORLI (COPACKAGED) | RELACORILANT | 100MG | CAPSULE;ORAL |
1 product